BioNTech SE (BNTX) Total Current Liabilities (2018 - 2025)
BioNTech SE (BNTX) posted Total Current Liabilities of $2.5 billion for Q4 2025, down 4.02% sequentially from $2.6 billion in Q3 2025, and down 7.51% YoY from $2.7 billion in Q4 2024.
BioNTech SE (BNTX) Total Current Liabilities (2018 - 2025) Analysis & Trends
BioNTech SE has reported Total Current Liabilities for 8 years, with the latest figure at $2.5 billion in Q4 2025.
- Quarterly Total Current Liabilities fell 7.51% year-over-year to $2.5 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.5 billion (down 7.51% YoY) and the FY2025 annual result came in at $2.4 billion, down 10.23% from the prior year.
- Total Current Liabilities retreated to $2.5 billion in Q4 2025 per BNTX's latest filing, from $2.6 billion in the prior quarter.
- Over five years, Total Current Liabilities peaked at $5.8 billion in Q3 2021 and troughed at $1.6 billion in Q1 2021.
- A 5-year average of $2.9 billion and a median of $2.6 billion in 2025 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2021 and 2023: Total Current Liabilities soared 1743.58% in 2021, then tumbled 61.52% in 2023.
- Over 5 years, Total Current Liabilities stood at $4.0 billion in 2021, then dropped by 24.42% to $3.0 billion in 2022, then fell by 26.0% to $2.2 billion in 2023, then increased by 21.03% to $2.7 billion in 2024, then retreated by 7.51% to $2.5 billion in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $2.5 billion, $2.6 billion, and $2.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | 2.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.49 Bn |
| Sep 30, 2025 | 2.60 Bn |
| Jun 30, 2025 | 2.10 Bn |
| Mar 31, 2025 | 1.61 Bn |
| Dec 31, 2024 | 2.70 Bn |
| Sep 30, 2024 | 2.77 Bn |
| Jun 30, 2024 | 2.61 Bn |
| Mar 31, 2024 | 1.74 Bn |
| Dec 31, 2023 | 2.23 Bn |
| Sep 30, 2023 | 1.97 Bn |
| Jun 30, 2023 | 1.98 Bn |
| Mar 31, 2023 | 1.66 Bn |
| Dec 31, 2022 | 3.01 Bn |
| Sep 30, 2022 | 3.99 Bn |
| Jun 30, 2022 | 4.19 Bn |
| Mar 31, 2022 | 4.33 Bn |
| Dec 31, 2021 | 3.98 Bn |
| Sep 30, 2021 | 5.78 Bn |
| Jun 30, 2021 | 3.81 Bn |
| Mar 31, 2021 | 1.58 Bn |